Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription Articles published in Metabolism Retrieve available abstracts of 114 articles: HTML format

Single Articles

April 2024
1. JEREMIAH SS, Moin ASM, Butler AE
   Virus-induced diabetes mellitus, revisiting infection etiology in light of SARS-CoV-2.
   Metabolism. 2024 Apr 18:155917. doi: 10.1016/j.metabol.2024.155917.
   PubMed     Abstract available
   
   
   
2. ROSENDO-SILVA D, Gomes PB, Rodrigues T, Viana S, et al
   Clinical and molecular profiling of human visceral adipose tissue reveals impairment of vascular architecture and remodeling as an early hallmark of dysfunction.
   Metabolism. 2024;153:155788.
   PubMed     Abstract available
   
   
   March 2024
3. HE Y, Qu L
   The role and mechanisms of non-coding RNAs in diabetic peripheral neuropathy.
   Metabolism. 2024 Mar 8:155833. doi: 10.1016/j.metabol.2024.155833.
   PubMed     Abstract available
   
   
   
4. HAN E, Lee BW, Kang ES, Cha BS, et al
   Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
   Metabolism. 2024;152:155789.
   PubMed     Abstract available
   
   
   
5. LIU C, Zheng Y, Hu S, Liang X, et al
   TOX3 deficiency mitigates hyperglycemia by suppressing hepatic gluconeogenesis through FoxO1.
   Metabolism. 2024;152:155766.
   PubMed     Abstract available
   
   
   
6. LAVILLE M, Robert M, Segrestin B
   Barriers to metabolic surgery and how to address them.
   Metabolism. 2024;152:155764.
   PubMed     Abstract available
   
   
   
7. KE Z, Lu Z, Li Q, Tong W, et al
   Intestinal glucose excretion: A potential mechanism for glycemic control.
   Metabolism. 2024;152:155743.
   PubMed     Abstract available
   
   
   February 2024
8. SARABHAI T, Kahl S, Gancheva S, Mastrototaro L, et al
   Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease.
   Metabolism. 2024;151:155762.
   PubMed     Abstract available
   
   
   
9. TSILINGIRIS D, Kokkinos A
   Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.
   Metabolism. 2024;151:155741.
   PubMed     Abstract available
   
   
   January 2024
10. PATEL S, Yan Z, Remedi MS
    Intermittent fasting protects beta-cell identity and function in a type-2 diabetes model.
    Metabolism. 2024 Jan 31:155813. doi: 10.1016/j.metabol.2024.155813.
    PubMed     Abstract available
    
    
    
11. KIM J, Kim M, Kim M, You YH, et al
    Dysregulation of autophagy activation induced by atorvastatin contributes to new-onset diabetes mellitus in western diet-fed mice.
    Metabolism. 2024;153:155795.
    PubMed     Abstract available
    
    
    
12. POPOVIC DS, Karakasis P, Koufakis T, Fragakis N, et al
    Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Metabolism. 2024 Jan 15:155791. doi: 10.1016/j.metabol.2024.155791.
    PubMed     Abstract available
    
    
    
13. KUGATHASAN L, Sridhar VS, Tommerdahl KL, Xu C, et al
    Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes.
    Metabolism. 2024 Jan 10:155785. doi: 10.1016/j.metabol.2024.155785.
    PubMed     Abstract available
    
    
    
14. YANG J, Yan Y, Yin X, Liu X, et al
    Bioengineering and vascularization strategies for islet organoids: advancing toward diabetes therapy.
    Metabolism. 2024 Jan 9:155786. doi: 10.1016/j.metabol.2024.155786.
    PubMed     Abstract available
    
    
    
15. DIEPENBROEK C, Rijnsburger M, van Irsen AAS, Eggels L, et al
    Dopamine in the nucleus accumbens shell controls systemic glucose metabolism via the lateral hypothalamus and hepatic vagal innervation in rodents.
    Metabolism. 2024;150:155696.
    PubMed     Abstract available
    
    
    December 2023
16. POPOVIC DS, Patoulias D, Gnudi L, Mantzoros CS, et al
    Diabetic kidney disease in type 1 diabetes: Challenges and differences from type 2 diabetes.
    Metabolism. 2023 Dec 18:155763. doi: 10.1016/j.metabol.2023.155763.
    PubMed    
    
    
    November 2023
17. ZUO F, Wang Y, Xu X, Ding R, et al
    CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease.
    Metabolism. 2023 Nov 10:155724. doi: 10.1016/j.metabol.2023.155724.
    PubMed     Abstract available
    
    
    
18. PENG J, Lu M, Wang P, Peng Y, et al
    The global burden of metabolic disease in children and adolescents: Data from the Global Burden of Disease 2000-2019.
    Metabolism. 2023;148:155691.
    PubMed    
    
    
    October 2023
19. STEINBACH E, Masi D, Ribeiro A, Serradas P, et al
    Upper small intestine microbiome in obesity and related metabolic disorders: A new field of investigation.
    Metabolism. 2023 Oct 24:155712. doi: 10.1016/j.metabol.2023.155712.
    PubMed     Abstract available
    
    
    
20. KARAKASIS P, Patoulias D, Pamporis K, Stachteas P, et al
    Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
    Metabolism. 2023 Oct 16:155710. doi: 10.1016/j.metabol.2023.155710.
    PubMed     Abstract available
    
    
    
21. VAN JAD, Luo Y, Danska JS, Dai F, et al
    Postpartum defects in inflammatory response after gestational diabetes precede progression to type 2 diabetes: a nested case-control study within the SWIFT study.
    Metabolism. 2023 Oct 4:155695. doi: 10.1016/j.metabol.2023.155695.
    PubMed     Abstract available
    
    
    September 2023
22. SHEN Y, Cheng L, Xu M, Wang W, et al
    SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis.
    Metabolism. 2023;146:155657.
    PubMed     Abstract available
    
    
    
23. CHEN W, Cui W, Wu J, Zheng W, et al
    Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion.
    Metabolism. 2023;146:155641.
    PubMed     Abstract available
    
    
    August 2023
24. SONG E, Hwang SY, Park MJ, Jang A, et al
    Additive impact of diabetes and sarcopenia on all-cause and cardiovascular mortality: A longitudinal nationwide population-based study.
    Metabolism. 2023 Aug 21:155678. doi: 10.1016/j.metabol.2023.155678.
    PubMed     Abstract available
    
    
    July 2023
25. FERNANDEZ-SAEZ EM, Losarcos M, Becerril S, Valenti V, et al
    Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD.
    Metabolism. 2023 Jul 28:155663. doi: 10.1016/j.metabol.2023.155663.
    PubMed     Abstract available
    
    
    
26. HU T, Wu Q, Yao Q, Yu J, et al
    PRDM16 exerts critical role in myocardial metabolism and energetics in type 2 diabetes induced cardiomyopathy.
    Metabolism. 2023 Jul 9:155658. doi: 10.1016/j.metabol.2023.155658.
    PubMed     Abstract available
    
    
    June 2023
27. GOLABI P, Paik JM, Kumar A, Al Shabeeb R, et al
    Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
    Metabolism. 2023 Jun 26:155642. doi: 10.1016/j.metabol.2023.155642.
    PubMed     Abstract available
    
    
    
28. JARVIS PRE, Cardin JL, Nisevich-Bede PM, McCarter JP, et al
    Continuous glucose monitoring in a healthy population: understanding the post-prandial glycemic response in individuals without diabetes mellitus.
    Metabolism. 2023 Jun 23:155640. doi: 10.1016/j.metabol.2023.155640.
    PubMed     Abstract available
    
    
    
29. WEI F, Gu Y, He L, Kapoor A, et al
    HSD17B6 delays type 2 diabetes development via inhibiting SREBP activation.
    Metabolism. 2023;145:155631.
    PubMed     Abstract available
    
    
    May 2023
30. HU J, Chen X, Luo Y, Yang J, et al
    Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses.
    Metabolism. 2023;145:155593.
    PubMed     Abstract available
    
    
    
31. PENG Y, Wang P, Gong J, Liu F, et al
    Association between the Finnish Diabetes Risk Score and cancer in middle-aged and older adults: Involvement of inflammation.
    Metabolism. 2023 May 8:155586. doi: 10.1016/j.metabol.2023.155586.
    PubMed     Abstract available
    
    
    
32. HASHIMOTO Y, Takahashi F, Okamura T, Hamaguchi M, et al
    Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes.
    Metabolism. 2023 May 6:155585. doi: 10.1016/j.metabol.2023.155585.
    PubMed     Abstract available
    
    
    
33. YU Q, Zhao G, Liu J, Peng Y, et al
    The role of histone deacetylases in cardiac energy metabolism in heart diseases.
    Metabolism. 2023;142:155532.
    PubMed     Abstract available
    
    
    
34. CHEN X, Merovci A, DeFronzo RA, Tripathy D, et al
    Chronic physiologic hyperglycemia impairs insulin-mediated suppression of plasma glucagon concentration in healthy humans.
    Metabolism. 2023;142:155512.
    PubMed     Abstract available
    
    
    April 2023
35. ZIEGLER D, Reiners K, Strom A, Obeid R, et al
    Association between diabetes and thiamine status - A systematic review and meta-analysis.
    Metabolism. 2023 Apr 22:155565. doi: 10.1016/j.metabol.2023.155565.
    PubMed     Abstract available
    
    
    
36. CHONG B, Kong G, Shankar K, Chew HSJ, et al
    The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000-2019.
    Metabolism. 2023;141:155402.
    PubMed     Abstract available
    
    
    March 2023
37. VEELEN A, Andriessen C, Op den Kamp Y, Erazo-Tapia E, et al
    Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial.
    Metabolism. 2023;140:155396.
    PubMed     Abstract available
    
    
    
38. GASBARRINO K, Hafiane A, Gianopoulos I, Zheng H, et al
    Relationship between circulating adipokines and cholesterol efflux in subjects with severe carotid atherosclerosis.
    Metabolism. 2023;140:155381.
    PubMed     Abstract available
    
    
    February 2023
39. HWANG YC, Ahn HY, Jun JE, Jeong IK, et al
    Subtypes of type 2 diabetes and their association with outcomes in Korean adults - A cluster analysis of community-based prospective cohort.
    Metabolism. 2023;141:155514.
    PubMed     Abstract available
    
    
    
40. YAN H, Meng Y, Li X, Xiang R, et al
    FAM3A maintains metabolic homeostasis by interacting with F1-ATP synthase to regulate the activity and assembly of ATP synthase.
    Metabolism. 2023;139:155372.
    PubMed     Abstract available
    
    
    January 2023
41. BENEDICTE G, Sara F, Paul L, Laetitia N, et al
    Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort.
    Metabolism. 2023 Jan 30:155412. doi: 10.1016/j.metabol.2023.155412.
    PubMed     Abstract available
    
    
    
42. ZHANG S, Stubbendorff A, Olsson K, Ericson U, et al
    Adherence to the EAT-Lancet diet, genetic susceptibility, and risk of type 2 diabetes in Swedish adults.
    Metabolism. 2023 Jan 19:155401. doi: 10.1016/j.metabol.2023.155401.
    PubMed     Abstract available
    
    
    
43. DU F, Liu M, Wang J, Hu L, et al
    Metformin coordinates with mesenchymal cells to promote VEGF-mediated angiogenesis in diabetic wound healing through Akt/mTOR activation.
    Metabolism. 2023 Jan 7:155398. doi: 10.1016/j.metabol.2023.155398.
    PubMed     Abstract available
    
    
    December 2022
44. LI S, Xu Z, Lin Z, Xiao H, et al
    Fyn deficiency inhibits oxidative stress by decreasing c-Cbl-mediated ubiquitination of Sirt1 to attenuate diabetic renal fibrosis.
    Metabolism. 2022 Dec 17:155378. doi: 10.1016/j.metabol.2022.155378.
    PubMed     Abstract available
    
    
    
45. DU L, Chen Y, Shi J, Yu X, et al
    Inhibition of S100A8/A9 ameliorates renal interstitial fibrosis in diabetic nephropathy.
    Metabolism. 2022 Dec 12:155376. doi: 10.1016/j.metabol.2022.155376.
    PubMed     Abstract available
    
    
    
46. ZHANG J, Wu Y, Zhang J, Zhang R, et al
    ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease.
    Metabolism. 2022 Dec 12:155377. doi: 10.1016/j.metabol.2022.155377.
    PubMed     Abstract available
    
    
    
47. WATKINS JD, Carter S, Atkinson G, Koumanov F, et al
    Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies.
    Metabolism. 2022 Dec 8:155375. doi: 10.1016/j.metabol.2022.155375.
    PubMed     Abstract available
    
    
    
48. LARSSON SC, Wang L, Li X, Jiang F, et al
    Circulating lipoprotein(a) levels and health outcomes: Phenome-wide Mendelian randomization and disease-trajectory analyses.
    Metabolism. 2022;137:155347.
    PubMed     Abstract available
    
    
    
49. SANOUDOU D, Mantzoros CS, Hill MA
    Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?
    Metabolism. 2022;137:155309.
    PubMed    
    
    
    November 2022
50. ANGELIDI AM, Kokkinos A, Sanoudou D, Connelly MA, et al
    Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Metabolism. 2022 Nov 11:155346. doi: 10.1016/j.metabol.2022.155346.
    PubMed     Abstract available
    
    
    
51. LIU Z, Zhang L, Qian C, Zhou Y, et al
    Recurrent hypoglycemia increases hepatic gluconeogenesis without affecting glycogen metabolism or systemic lipolysis in rat.
    Metabolism. 2022;136:155310.
    PubMed     Abstract available
    
    
    
52. YE J, Zhuang X, Li X, Gong X, et al
    Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation.
    Metabolism. 2022;136:155294.
    PubMed     Abstract available
    
    
    
53. MARKU A, Da Dalt L, Galli A, Dule N, et al
    Pancreatic PCSK9 controls the organization of the beta-cell secretory pathway via LDLR-cholesterol axis.
    Metabolism. 2022;136:155291.
    PubMed     Abstract available
    
    
    
54. VALENZUELA-VALLEJO L, Guatibonza-Garcia V, Mantzoros CS
    Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?
    Metabolism. 2022;136:155248.
    PubMed     Abstract available
    
    
    October 2022
55. HUI Y, Xu Z, Li J, Kuang L, et al
    Nonenzymatic function of DPP4 promotes diabetes-associated cognitive dysfunction through IGF-2R/PKA/SP1/ERp29/IP3R2 pathway-mediated impairment of Treg function and M1 microglia polarization.
    Metabolism. 2022 Oct 24:155340. doi: 10.1016/j.metabol.2022.155340.
    PubMed     Abstract available
    
    
    
56. LI X, Yang Y, Chen Z
    Downregulation of the m(6)A reader protein YTHDC1 leads to islet beta-cell failure and diabetes.
    Metabolism. 2022 Oct 24:155339. doi: 10.1016/j.metabol.2022.155339.
    PubMed     Abstract available
    
    
    
57. DEMARSILIS A, Reddy N, Boutari C, Filippaios A, et al
    Pharmacotherapy of type 2 diabetes: An update and future directions.
    Metabolism. 2022 Oct 11:155332. doi: 10.1016/j.metabol.2022.155332.
    PubMed     Abstract available
    
    
    
58. LAI H, Yang M, Sun M, Pan B, et al
    Risk of incident diabetes after COVID-19 infection: A systematic review and meta-analysis.
    Metabolism. 2022 Oct 8:155330. doi: 10.1016/j.metabol.2022.155330.
    PubMed     Abstract available
    
    
    
59. LARSSON SC, Michaelsson K, Mola-Caminal M, Hoijer J, et al
    Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH.
    Metabolism. 2022;137:155329.
    PubMed     Abstract available
    
    
    
60. LIU Z, Suo C, Fan H, Zhang T, et al
    Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases.
    Metabolism. 2022;135:155270.
    PubMed     Abstract available
    
    
    
61. KAPRALOU AN, Chrousos GP
    Metabolic effects of truncal vagotomy when combined with bariatric-metabolic surgery.
    Metabolism. 2022;135:155263.
    PubMed     Abstract available
    
    
    
62. DEMARSILIS A, Mantzoros CS
    The continuum of insulin development viewed in the context of a collaborative process toward leveraging science to save lives: Following the trail of publications and patents one century after insulin's first use in humans.
    Metabolism. 2022;135:155251.
    PubMed     Abstract available
    
    
    September 2022
63. CHANG X, Li Y, Cai C, Wu F, et al
    Mitochondrial quality control mechanisms as molecular targets in diabetic heart.
    Metabolism. 2022 Sep 17:155313. doi: 10.1016/j.metabol.2022.155313.
    PubMed     Abstract available
    
    
    
64. LEE M, Jeong K, Park YR, Rhee Y, et al
    Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database.
    Metabolism. 2022 Sep 16:155311. doi: 10.1016/j.metabol.2022.155311.
    PubMed     Abstract available
    
    
    
65. LIN CC, Li CI, Juan YL, Liu CS, et al
    Joint effect of blood pressure and glycemic variation on the risk of cardiovascular morbidity and mortality in persons with type 2 diabetes.
    Metabolism. 2022;136:155308.
    PubMed     Abstract available
    
    
    
66. TRICO D, Mengozzi A, Baldi S, Bizzotto R, et al
    Lipid-induced glucose intolerance is driven by impaired glucose kinetics and insulin metabolism in healthy individuals.
    Metabolism. 2022;134:155247.
    PubMed     Abstract available
    
    
    August 2022
67. WEN Y, Chen X, Feng H, Wang X, et al
    Kdm6a deficiency in microglia/macrophages epigenetically silences Lcn2 expression and reduces photoreceptor dysfunction in diabetic retinopathy.
    Metabolism. 2022 Aug 19:155293. doi: 10.1016/j.metabol.2022.155293.
    PubMed     Abstract available
    
    
    
68. BAUMANN A, Burger K, Brandt A, Staltner R, et al
    GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease.
    Metabolism. 2022;133:155233.
    PubMed     Abstract available
    
    
    
69. KOUFAKIS T, Popovic DS, Metallidis S, Kotsa K, et al
    COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong.
    Metabolism. 2022;133:155221.
    PubMed    
    
    
    
70. TRIGGLE CR, Mohammed I, Bshesh K, Marei I, et al
    Metformin: Is it a drug for all reasons and diseases?
    Metabolism. 2022;133:155223.
    PubMed     Abstract available
    
    
    July 2022
71. SAVIKJ M, Stocks B, Sato S, Caidahl K, et al
    Exercise timing influences multi-tissue metabolome and skeletal muscle proteome profiles in type 2 diabetic patients - A randomized crossover trial.
    Metabolism. 2022 Jul 28:155268. doi: 10.1016/j.metabol.2022.155268.
    PubMed     Abstract available
    
    
    June 2022
72. LUO Q, Liang W, Zhang Z, Zhu Z, et al
    Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism.
    Metabolism. 2022 Jun 30:155245. doi: 10.1016/j.metabol.2022.155245.
    PubMed     Abstract available
    
    
    
73. SARDU C, Massimo Massetti M, Rambaldi P, Gatta G, et al
    SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study.
    Metabolism. 2022 Jun 19:155243. doi: 10.1016/j.metabol.2022.155243.
    PubMed     Abstract available
    
    
    
74. VERMA M, Loh NY, Sabaratnam R, Vasan SK, et al
    TCF7L2 plays a complex role in human adipose progenitor biology, which might contribute to genetic susceptibility to type 2 diabetes.
    Metabolism. 2022 Jun 10:155240. doi: 10.1016/j.metabol.2022.155240.
    PubMed     Abstract available
    
    
    
75. CAO Q, Zheng R, He R, Wang T, et al
    Use of the new guidelines on an earlier age threshold of 35years for diabetes screening can identify an additional 6.3 million undiagnosed individuals with diabetes and 72.3 million individuals with prediabetes among Chinese adults: An analysis of a n
    Metabolism. 2022 Jun 10:155238. doi: 10.1016/j.metabol.2022.155238.
    PubMed     Abstract available
    
    
    
76. XU C, Li H, Tang CK
    Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications.
    Metabolism. 2022;131:155180.
    PubMed     Abstract available
    
    
    
77. ZHAO Y, Jia X, Yang X, Bai X, et al
    Deacetylation of Caveolin-1 by Sirt6 induces autophagy and retards high glucose-stimulated LDL transcytosis and atherosclerosis formation.
    Metabolism. 2022;131:155162.
    PubMed     Abstract available
    
    
    May 2022
78. JEPSEN MR, Ostergaard JA, Conover CA, Wogensen L, et al
    Increased activity of the metalloproteinase PAPP-A promotes diabetes-induced glomerular hypertrophy.
    Metabolism. 2022 May 16:155218. doi: 10.1016/j.metabol.2022.155218.
    PubMed     Abstract available
    
    
    
79. XU C, Hou Y, Si K, Cao Z, et al
    Cardiorespiratory fitness, genetic susceptibility, inflammation and risk of incident type 2 diabetes: A population-based longitudinal study.
    Metabolism. 2022 May 16:155215. doi: 10.1016/j.metabol.2022.155215.
    PubMed     Abstract available
    
    
    April 2022
80. UM JH, Park SY, Hur JH, Lee HY, et al
    Bone morphogenic protein 9 is a novel thermogenic hepatokine secreted in response to cold exposure.
    Metabolism. 2022;129:155139.
    PubMed     Abstract available
    
    
    March 2022
81. NGUYEN NN, Ho DS, Nguyen HS, Ho DKN, et al
    Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.
    Metabolism. 2022;131:155196.
    PubMed     Abstract available
    
    
    
82. YAO L, Liang X, Qiao Y, Chen B, et al
    Mitochondrial dysfunction in diabetic tubulopathy.
    Metabolism. 2022;131:155195.
    PubMed     Abstract available
    
    
    
83. YANG T, Heng C, Zhou Y, Hu Y, et al
    Corrigendum to 'Targeting mammalian serine/threonine-protein kinase 4 through yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis [Metabolism Cl
    Metabolism. 2022;130:154963.
    PubMed    
    
    
    
84. CHEN Y, Yang Y, Liu Z, He L, et al
    Adiponectin promotes repair of renal tubular epithelial cells by regulating mitochondrial biogenesis and function.
    Metabolism. 2022;128:154959.
    PubMed     Abstract available
    
    
    
85. MAGKOS F, Lee MH, Lim M, Cook AR, et al
    Dynamic assessment of insulin secretion and insulin resistance in Asians with prediabetes.
    Metabolism. 2022;128:154957.
    PubMed     Abstract available
    
    
    February 2022
86. HUANG S, Wang J, Zhang L, Tian S, et al
    Ras guanine nucleotide-releasing protein-4 promotes renal inflammatory injury in type 2 diabetes mellitus.
    Metabolism. 2022 Feb 23:155177. doi: 10.1016/j.metabol.2022.155177.
    PubMed     Abstract available
    
    
    
87. SCHERNTHANER G, Brand K, Bailey CJ
    Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.
    Metabolism. 2022 Feb 7:155160. doi: 10.1016/j.metabol.2022.155160.
    PubMed     Abstract available
    
    
    
88. WARE J, Hovorka R
    Recent advances in closed-loop insulin delivery.
    Metabolism. 2022;127:154953.
    PubMed     Abstract available
    
    
    
89. FALCETTA P, Aragona M, Bertolotto A, Bianchi C, et al
    Insulin discovery: A pivotal point in medical history.
    Metabolism. 2022;127:154941.
    PubMed     Abstract available
    
    
    
90. CARUSO I, Giorgino F
    SGLT-2 inhibitors as cardio-renal protective agents.
    Metabolism. 2022;127:154937.
    PubMed     Abstract available
    
    
    January 2022
91. QU HQ, Qu J, Glessner J, Hakonarson H, et al
    Mendelian randomization study of obesity and type 2 diabetes in hospitalized COVID-19 patients.
    Metabolism. 2022 Jan 28:155156. doi: 10.1016/j.metabol.2022.155156.
    PubMed     Abstract available
    
    
    
92. ZHENG W, Guo J, Lu X, Qiao Y, et al
    cAMP-response element binding protein mediates podocyte injury in diabetic nephropathy by targeting lncRNA DLX6-AS1.
    Metabolism. 2022 Jan 27:155155. doi: 10.1016/j.metabol.2022.155155.
    PubMed     Abstract available
    
    
    
93. LEE J, Han K, Park SH, Kim MK, et al
    Associations of variability in body weight and glucose levels with the risk of hip fracture in people with diabetes.
    Metabolism. 2022 Jan 12:155135. doi: 10.1016/j.metabol.2022.155135.
    PubMed     Abstract available
    
    
    
94. BOLLI GB, Porcellati F, Lucidi P, Fanelli CG, et al
    One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs.
    Metabolism. 2022;126:154935.
    PubMed     Abstract available
    
    
    
95. CHU X, Raju RP
    Regulation of NAD(+) metabolism in aging and disease.
    Metabolism. 2022;126:154923.
    PubMed     Abstract available
    
    
    
96. ROSENSTOCK J, Del Prato S
    Basal weekly insulins: the way of the future!
    Metabolism. 2022;126:154924.
    PubMed     Abstract available
    
    
    
97. LO T, Lee Y, Tseng CY, Hu Y, et al
    Daily transient coating of the intestine leads to weight loss and improved glucose tolerance.
    Metabolism. 2022;126:154917.
    PubMed     Abstract available
    
    
    December 2021
98. THOMAS MC
    The clustering of Cardiovascular, Renal, Adipo-Metabolic and Liver disease with type 2 diabetes.
    Metabolism. 2021 Dec 24:154961. doi: 10.1016/j.metabol.2021.154961.
    PubMed     Abstract available
    
    
    
99. CORNEJO MA, Ortiz RM
    Body mass cycling and predictors of body mass regain and its impact on cardiometabolic health.
    Metabolism. 2021;125:154912.
    PubMed     Abstract available
    
    
    
100. MASTROTOTARO L, Roden M
     Insulin resistance and insulin sensitizing agents.
     Metabolism. 2021;125:154892.
     PubMed     Abstract available
     
     
     November 2021
101. ZHOU C, Zhang Z, Liu M, Zhang Y, et al
     Corrigendum to 'Dietary carbohydrate intake and new-onset diabetes: A Nationwide Cohort Study in China' [Metab Clin Exp 123 (2021) 154865].
     Metabolism. 2021;127:154940.
     PubMed    
     
     
     
102. MARFELLA R, D'Onofrio N, Trotta MC, Sardu C, et al
     Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts.
     Metabolism. 2021;127:154936.
     PubMed     Abstract available
     
     
     
103. HOME P
     Future directions in insulin therapy.
     Metabolism. 2021;124:154889.
     PubMed     Abstract available
     
     
     
104. WEIR GC, Butler PC, Bonner-Weir S
     The beta-cell glucose toxicity hypothesis: Attractive but difficult to prove.
     Metabolism. 2021;124:154870.
     PubMed     Abstract available
     
     
     October 2021
105. KOWLURU RA, Mohammad G
     Epigenetic modifications in diabetes.
     Metabolism. 2021 Oct 26:154920. doi: 10.1016/j.metabol.2021.154920.
     PubMed     Abstract available
     
     
     
106. ZHAO Z, Deng X, Jia J, Zhao L, et al
     Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K/Akt signaling pathway in diabetic mice.
     Metabolism. 2021 Oct 26:154921. doi: 10.1016/j.metabol.2021.154921.
     PubMed     Abstract available
     
     
     
107. LIU H, Sridhar VS, Boulet J, Dharia A, et al
     Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
     Metabolism. 2021 Oct 23:154918. doi: 10.1016/j.metabol.2021.154918.
     PubMed     Abstract available
     
     
     
108. ZHANG Y, Cai Y, Zhang H, Zhang J, et al
     Brown adipose tissue transplantation ameliorates diabetic nephropathy through the miR-30b pathway by targeting Runx1.
     Metabolism. 2021 Oct 16:154916. doi: 10.1016/j.metabol.2021.154916.
     PubMed     Abstract available
     
     
     
109. JANKAUSKAS SS, Kansakar U, Varzideh F, Wilson S, et al
     Heart failure in diabetes.
     Metabolism. 2021 Oct 7:154910. doi: 10.1016/j.metabol.2021.154910.
     PubMed     Abstract available
     
     
     September 2021
110. RIZZO M, Nauck MA, Mantzoros CS
     Incretin-based therapies in 2021 - Current status and perspectives for the future.
     Metabolism. 2021;122:154843.
     PubMed    
     
     
     
111. ZHANG X, Zhuang Y, Qin T, Chang M, et al
     Suppressor of cytokine signalling-2 controls hepatic gluconeogenesis and hyperglycemia by modulating JAK2/STAT5 signalling pathway.
     Metabolism. 2021;122:154823.
     PubMed     Abstract available
     
     
     August 2021
112. LANDRY T, Shookster D, Huang H
     Circulating alpha-klotho regulates metabolism via distinct central and peripheral mechanisms.
     Metabolism. 2021;121:154819.
     PubMed     Abstract available
     
     
     July 2021
113. ARVIND A, Memel ZN, Philpotts LL, Zheng H, et al
     Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
     Metabolism. 2021;120:154780.
     PubMed     Abstract available
     
     
     August 2020
114. ZHU Z, Hasegawa K, Ma B, Fujiogi M, et al
     Obesity & genetic predisposition with COVID-19.
     Metabolism. 2020 Aug 21:154345. doi: 10.1016/j.metabol.2020.154345.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.